Third Generation Sequencing Market to Hit $23.92 Billion, Globally, by 2030 at 13.1% CAGR: Coherent Market Insights

Third Generation Sequencing, also known as long-read sequencing, represents a breakthrough in the realm of genomics. Unlike the previous methods which required DNA fragmentation, TGS reads long DNA molecules directly, offering several advantages.

Burlingame, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Coherent Market Insights published a report, titled, “Third Generation Sequencing Market, By Type of Technology (Single-molecule real-time (SMRT) sequencing, Nanopore sequencing, Others), By Product (Instruments, Reagents and consumables, Services), By Application (Genome sequencing, Epigenetics, Transcriptomics, Metagenomics, Others), By End User (Academic and research institutes, Pharmaceutical and biotechnology companies, Hospitals and clinics, Contract research organizations (CROs), Others): Global Size & Share Analysis - Growth Trends and Forecasts (2023 - 2030).”According to the report, the global Third Generation Sequencing industry was estimated at $8.93 billion in 2022, and is anticipated to hit $23.92 billion by 2030, registering a CAGR of 13.1% from 2023 to 2030.  

Third-generation sequencing (TGS) technologies are significant traction in the genomics field as it helps to overcome few limitations associated with earlier sequencing generations, such as the need for amplification and the generation of short reads. Growing need for DNA or RNA in real-time is expected to foster the market growth. Moreover, it gives much longer sequencing read.

Request Sample Report at:

Key Trends and Analysis of the Global Third Generation Sequencing Market:

Growing trend of precision medicine to propel market growth. Precision medicine helps to tailor individual treatment based on their genetic makeup. This is augmenting demand for comprehensive genomic information. Third-generation sequencing plays important role in giving genetic information. This is beneficial in taking personalized treatment decisions.

Third Generation Sequencing Market Report Coverage

Report CoverageDetails
 Forecast Period 2023–2030
 Base Year 2022 
 Market Size in 2022 $8.93 billion  
 Market Size in 2030$23.92 billion  
 CAGR 13.1% 
 No. of Pages in Report 155 
 Segments covered By Type of Technology, By Product, By Application, By End User
 Growth Drivers  
  • Longer Read Lengths
  • Real-Time Sequencing
  • Direct Sequencing
  • Growing Demand for Precision Medicine
 Restraints & Challenges
  • High Cost
  • Technical Challenges
  • Data Analysis Complexity

Key Developments

In March 2023, Sophia Genetics a cloud-native software company in the healthcare space, announced a new partnership with Qiagen N.V. that will pair QIAseq reagent technology with the SOPHiA DDM™ platform to enhance tumor analysis through next-generation sequencing (NGS)

In December 2020,, a provider of cutting-edge “omics” solutions, and Fujirebio Europe announced that they have been awarded a 720K EURO research grant from Flanders Innovation & Entrepreneurship (VLAIO) to develop a clinical in vitro diagnostics (IVD) platform incorporating third generation sequencing (TGS) technologies.

Buy Now & Get Exclusive Discount on this Business Complete Report:

Market Drivers:

Growing genomic research to propel third-generation sequencing market growth

Increasing genomic research and growing biotechnology sector is propelling growth of the third-generation sequencing market. In September 2021, India’s genomics lab Nucleome launched its most advanced genomics lab NKC Centre for genomics research. Laboratory was inaugurated by the Defence Minister of India, Shri Rajanth Singh Ji and Chief Minister of Madhya Pradesh, Shri Shivraj Singh Chauhan Ji. Principal Scientific Advisor delivered the keynote lecture to the Government of India Prof K VijayRaghvan Ji.

Growing need for infectious disease surveillance is anticipated to propel market growth

Third-generation sequencing platforms with real-time sequencing provide rapid identification and characterization of infectious pathogens. This can support the surveillance and response to disease outbreaks, allowing timely interference strategies and informed public health decisions.

Market Restrain:

High cost is a key factor to hamper market growth

Third-generation sequencing is expensive than second-generation sequencing techniques. Cost of instrument, data processing, and consumables increase the overall cost of the process. This makes it expensive when compared to other process. Thus, high cost of third-generation sequencing is expected to augment market growth.

Market Opportunities:

Expanding application of TGS to serve major growth opportunities

Third-generation sequencing technologies are widely gaining adoption in range of fields outside genomics research. Some of the emerging application of third-generation sequencing are precision medicine, environmental studies, clinical diagnostics, agriculture, and more. The ability to create long-read sequences and capture complex genomic information opens up new possibilities for exploration of various applications.

Request Customization of this Report:

Key Market Takeaways:

Global third generation sequencing market is expected to exhibit a CAGR of 13.1% during the forecast period, owing to increasing genomic research, expanding biotechnology sector, and growing demand for personalized medicine.

On the basis of Type of Technology, Single-molecule real-time (SMRT) sequencing segment is expected to hold a dominant position, as it gives real-time result. It can be used to identify DNA modification.

On the basis of Product, instruments segment is expected to hold a dominant position, owing to the fact that they are the very important component of TGS process.

On the basis of Application, genome sequencing segment is expected to hold a dominant position. TGS allow researchers to get more accurate and complete genomic information

On the basis of End User, academic and research institutes segment is expected to hold a dominant position, owing to the growing number of genomic research.

On the basis of region, North America is expected to hold a dominant position over the forecast period, due to growing investment in genomic research, presence of well-established healthcare infrastructure, and strong presence of key sequencing companies.

Key players operating in the global Third Generation Sequencing market include Pacific Biosciences of California, Inc., Oxford Nanopore Technologies, Ltd., BGI Genomics Co., Ltd., F. Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., GenapSys Inc., Loop Genomics, Nabsys, Inc., Genia Technologies, Inc., Stratos Genomics, Inc., GATC Biotech AG, Phase Genomics, Inc.

Detailed Segmentation:

  • Global Third Generation Sequencing Market, By Technology:
    • Single-Molecule Real-Time (SMRT) Sequencing
    • Nanopore Sequencing
    • Others
  • Global Third Generation Sequencing Market, By Product:
    • Instruments
    • Reagents and Consumables
    • Services
  • Global Third Generation Sequencing Market, By Application:
    • Genome Sequencing
    • Epigenetics
    • Transcriptomics
    • Metagenomics
    • Others
  • Global Third Generation Sequencing Market, By End user:
    • Academic and Research Institutes
    • Pharmaceutical and Biotechnology Companies
    • Hospitals and Clinics
    • Contract Research Organizations (CROs)
    • Others
  • Global Third Generation Sequencing Market, By Geography:
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • Italy
      • U.K.
      • France
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • Australia
      • India
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • Israel
      • South Africa
      • Rest of Middle East & Africa

Related Market Intelligence Reports:

Biologics Outsourcing Market, By Product and Service Type (Product, (Antibodies, Recombinant Proteins, Vaccines, Others), Services, (Cell Development, Process Development, Analytical Testing, cGMP Manufacturing, Others)), By Source (Mammalian, Microbial), By Application (Oncology, Cellular and Gene Therapy, Blood & Blood-Related Products Development, Vaccine Development, Stem Cell Research, Others) By End User (Pharmaceutical Industries, Biotechnology Industries, CDMO), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Pituitary Cancer Market,By Cancer Type (Pituitary Adenoma (Benign Tumor), Pituitary Carcinoma (Malignant Tumor)), By Hormone Type (Prolactinoma, Growth Hormone-Secreting Tumor (Acromegaly), Adrenocorticotropic Hormone-Secreting Tumor (Cushing\\\'s Disease), Thyroid-Stimulating Hormone-Secreting Tumor (TSHoma), Gonadotropin-Secreting Tumor), By Treatment Type (Surgery, Radiation Therapy, Medications (e.g., dopamine agonists, somatostatin analogs, hormone replacement therapy), Targeted Therapy, Chemotherapy), By Age Group (Pediatric, Adult), By End-User (Hospitals, Specialty Clinics, Cancer Treatment Centers, Research Institutes) , and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Biopharma Buffer Market, By Type (Pre-formulated Buffers, Customized Buffers, Concentrated Buffers, Others), By Application (Cell Culture, Purification, Formulation), By End User (Biopharmaceutical Companies, Contract Research Organizations, Academic & Research Institutes), By Buffer Component (Amino Acids, Acetic Acid, Phosphate, Histidine, Others), By Buffer Preparation (Liquid, Powder), By Material Form (Dry, Liquid), By Region (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Browse through Coherent Market Insights Pharmaceutical Research Reports.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedInTwitter


Contact Data